阴道孕酮与宫颈环扎联合用于短宫颈的互补效应
本文讨论经阴道超声发现短宫颈(CL)孕妇的治疗策略。基于随机对照试验(RCT)及其荟萃分析的一级证据,文章提出阴道孕酮与宫颈环扎可能针对自发性早产的不同机制发挥互补作用,联合使用与早产发生率降低相关,但现有证据有限,多为观察性、回顾性研究,仍需更多研究。
要点
- 无自发性早产史、24周前TVU CL≤25 mm者推荐阴道孕酮。
- 有自发性早产史者通常16周启动阴道孕酮,出现短宫颈时推荐UIC。
- 联合阴道孕酮与环扎的证据有限,尚需高质量研究验证。
核心结论
- 阴道孕酮与宫颈环扎可能通过不同机制互补,联合使用与早产发生率降低相关,但证据仍有限。
研究设计与样本
- 本文为综述性文章,汇总RCT及其荟萃分析等证据,未报告新的研究样本量。
主要发现
- 有限但逐渐增多的数据显示,24周前TVU短宫颈者联合使用阴道孕酮与环扎,与单用阴道孕酮或单用环扎相比早产发生率降低。
- 现有联合用药证据多为观察性、回顾性研究,方法学质量有限。
关键数值与推荐
- 单胎、无既往自发性早产史者,24周前TVU CL≤25 mm推荐阴道孕酮。
- 宫颈进行性缩短(如24周前CL≤20 mm)可考虑UIC,并可考虑继续阴道孕酮。
- 单胎、有既往自发性早产史者通常16周启动阴道孕酮;若24周前TVU CL<25 mm,推荐UIC,也可考虑继续阴道孕酮。
临床怎么用
- 对短宫颈孕妇应按既往自发性早产史分层选择阴道孕酮或环扎,并关注联合方案的潜在互补效应。
局限性
- 联合使用孕酮与环扎的证据有限,研究数量少,多为观察性、回顾性且方法学质量有限,需更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of patients with a short cervical length (CL) on transvaginal ultrasound (TVU) often involves therapy with vaginal progesterone and/or cervical cerclage. Although these interventions are frequently viewed as alternative strategies, they may also represent complementary approaches targeting different mechanisms involved in spontaneous preterm birth. As in other areas of medicine, therapies with different mechanisms are often used together rather than as mutually exclusive options. In line with current level 1 evidence from randomized controlled trials (RCTs) and meta-analyses of RCTs on either vaginal progesterone or cerclage, in singleton gestations with no prior spontaneous preterm birth (SPTB), vaginal progesterone is recommended when a TVU CL≤25 mm before 24 weeks is identified; if progressive cervical shortening occurs (eg, CL≤20 mm before 24 weeks), UIC may be considered and continuation of vaginal progesterone may be considered. Similarly, in singleton gestations with prior SPTB, vaginal progesterone is typically initiated at 16 weeks, and if a short cervix (TVU CL<25 mm before 24 weeks) develops, UIC is recommended, continuation of vaginal progesterone may also be considered. In addition, there are limited but growing data that vaginal progesterone and cerclage used together for a short TVU CL before 24 weeks have potential complementary effects, with decreased incidence of PTB compared to using either vaginal progesterone alone, or cerclage alone. Overall, the available evidence on the combined use of progesterone and cerclage remains limited, with relatively few studies, most of which are observational, retrospective and of modest methodological quality; therefore, more research is needed. International guidelines should address the use of this combined approach of both vaginal progesterone and cerclage for a short mid-trimester TVU CL.
引用
- Berghella V, Paladino I, Gulersen M, et al. Progesterone and cerclage together for short cervix: evaluating potential complementary effects for improved preterm birth prevention. Am J Obstet Gynecol MFM. 2026. PMID: 42431373. doi:10.1016/j.ajogmf.2026.102055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。